Chapter 5.3 Experimental models: Panic and fear

Handbook of Behavioral Neuroscience

Volumn 17, Issue , 2008, Pages 413-435

  Esquivel, Gabriel ^a   Schruers, Koen ^a   Griez, Eric ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

carbon dioxide; cholecystokinin; doxapram; experimental models; fear; lactate; panic; voluntary hyperventilation

Indexed keywords

EID: 67649998176     PISSN: 15697339     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-7339(07)00019-7     Document Type: Review

References (225)

1. Abelson J.L., Khan S., Liberzon I., and Young E.A. HPA axis activity in patients with panic disorder: review and synthesis of four studies. Depress. Anxiety 24 (2006) 66-76
2. Abelson J.L., and Nesse R.M. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses. Biol. Psychiatry 36 (1994) 73-83
3. Abelson J.L., Nesse R.M., and Vinik A.I. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. Biol. Psychiatry 36 (1994) 84-96
4. Andreatini R., Blanchard C., Blanchard R., Brandao M.L., Carobrez A.P., and Griebel G. The brain decade in debate: II. Panic or anxiety? From animal models to a neurobiological basis. Braz. J. Med. Biol. Res. 34 (2001) 145-154
5. Argyropoulos S.V., Bailey J.E., Hood S.D., Kendrick A.H., Rich A.S., and Laszlo G. Inhalation of 35% CO(2) results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology 27 (2002) 715-729
6. 2 in human volunteers. Depress. Anxiety 21 (2005) 18-25
7. 2 challenge?. J. Psychopharmacol. 17 (2003) 252-259
8. 2 model of GAD using paroxetine and lorazepam in healthy volunteers. J. Psychopharmacol. 21 (2007) 42-49
9. Ball S., and Shekhar A. Basilar artery response to hyperventilation in panic disorder. Am. J. Psychiatry 154 (1997) 1603-1604
10. Balon R., Yeragani V.K., and Pohl R. Phenomenological comparison of dextrose, lactate, and isoproterenol associated panic attacks. Psychiatry Res. 26 (1988) 43-50
11. 2 challenge in panic disorder: optimization by receiver operating characteristic (ROC) analysis. J. Psychiatr. Res. 29 (1995) 111-119
12. Bell C., Forshall S., Adrover M., Nash J., Hood S., and Argyropoulos S. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J. Psychopharmacol. 16 (2002) 5-14
13. 2-induced panic attacks: a twin study. Am. J. Psychiatry 155 (1998) 1184-1188
14. Bertoglio L.J., de Bortoli V.C., and Zangrossi Jr. H. Cholecystokinin-2 receptors modulate freezing and escape behaviors evoked by the electrical stimulation of the rat dorsolateral periaqueductal gray. Brain Res. 1156 (2007) 133-138
15. Bickler P.E., Litt L., Banville D.L., and Severinghaus J.W. Effects of acetazolamide on cerebral acid-base balance. J. Appl. Physiol. 65 (1988) 422-427
16. Blanchard D.C., Griebel G., and Blanchard R.J. The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic. Eur. J. Pharmacol. 463 (2003) 97-116
17. Bourin M., Baker G.B., and Bradwejn J. Neurobiology of panic disorder. J. Psychosom. Res. 44 (1998) 163-180
18. Bouton M.E., Mineka S., and Barlow D.H. A modern learning theory perspective on the etiology of panic disorder. Psychol. Rev. 108 (2001) 4-32
19. Bradwejn J., and Koszycki D. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am. J. Psychiatry 151 (1994) 261-263
20. Bradwejn J., Koszycki D., Annable L., Couetoux du Tertre A., Reines S., and Karkanias C. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. Biol. Psychiatry 32 (1992) 903-912
21. Bradwejn J., Koszycki D., and Bourin M. Dose ranging study of the effects of cholecystokinin in healthy volunteers. J. Psychiatry Neurosci. 16 (1991) 91-95
22. Bradwejn J., Koszycki D., Couetoux du Tertre A., Paradis M., and Bourin M. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Psychopharmacol. (Berl.) 114 (1994) 257-261
23. Bradwejn J., Koszycki D., Couetoux du Tertre A., van Megen H., den Boer J., and Westenberg H. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psychiatry 51 (1994) 486-493
24. Bradwejn J., Koszycki D., and Meterissian G. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can. j. Psychiatry 35 (1990) 83-85
25. Bradwejn J., Koszycki D., Paradis M., Reece P., Hinton J., and Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol. Psychiatry 38 (1995) 742-746
26. Bradwejn J., Koszycki D., Payeur R., Bourin M., and Borthwick H. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am. J. Psychiatry 149 (1992) 962-964
27. Bradwejn J., LeGrand J.M., Koszycki D., Bates J.H., and Bourin M. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. Am. J. Psychiatry 155 (1998) 280-282
28. Brawman-Mintzer O., Lydiard R.B., Bradwejn J., Villarreal G., Knapp R., and Emmanuel N. Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am. J. Psychiatry 154 (1997) 700-702
29. Briggs A.C., Stretch D.D., and Brandon S. Subtyping of panic disorder by symptom profile. Br. J. Psychiatry 163 (1993) 201-209
30. Broocks A., Bandelow B., Pekrun G., George A., Meyer T., and Bartmann U. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am. J. Psychiatry 155 (1998) 603-609
31. Bruce M., Scott N., Shine P., and Lader M. Anxiogenic effects of caffeine in patients with anxiety disorders. Arch. Gen. Psychiatry 49 (1992) 867-869
32. Buller R., von Bardeleben U., Maier W., and Benkert O. Specificity of lactate response in panic disorder, panic with concurrent depression and major depression. J. Affect. Disord. 16 (1989) 109-113
33. Canteras N.S. The medial hypothalamic defensive system: hodological organization and functional implications. Pharmacol. Biochem. Behav. 71 (2002) 481-491
34. Carr D.B., and Sheehan D.V. Panic anxiety: a new biological model. J. Clin. Psychiatry 45 (1984) 323-330
35. Charney D.S. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr. Scand. Suppl. 108 (2003) 38-50
36. Charney D.S., and Heninger G.R. Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term imipramine treatment. Arch. Gen. Psychiatry 42 (1985) 473-481
37. Charney D.S., and Heninger G.R. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch. Gen. Psychiatry 43 (1986) 1042-1054
38. Charney D.S., Heninger G.R., and Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch. Gen. Psychiatry 41 (1984) 751-763
39. Charney D.S., Woods S.W., and Heninger G.R. Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res. 27 (1989) 173-182
40. Cohen M.E., and White P.D. Life situations, emotions, and neurocirculatory asthenia (anxiety neurosis, neurasthenia, effort syndrome). Psychosom. Med. 13 (1951) 335-357
41. Coplan J.D., Goetz R., Klein D.F., Papp L.A., Fyer A.J., and Liebowitz M.R. Plasma cortisol concentrations preceding lactate-induced panic. Psychological, biochemical, and physiological correlates. Arch. Gen. Psychiatry 55 (1998) 130-136
42. Coplan J.D., Liebowitz M.R., Gorman J.M., Fyer A.J., Dillon D.J., and Campeas R.B. Noradrenergic function in panic disorder. Effects of intravenous clonidine pretreatment on lactate induced panic. Biol. Psychiatry 31 (1992) 135-146
43. 2-stimulated breathing in man. J. Physiol. 488 (1995) 77-84
44. Cotton J.F., Keshavaprasad B., Laster M.J., Eger II E.I., and Yost C.S. The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth. Analg. 102 (2006) 779-785
45. Cowley D.S., Dager S.R., and Dunner D.L. Lactate-induced panic in primary affective disorder. Am. J. Psychiatry 143 (1986) 646-648
46. Cowley D.S., Dager S.R., McClellan J., Roy-Byrne P.P., and Dunner D.L. Response to lactate infusion in generalized anxiety disorder. Biol. Psychiatry 24 (1988) 409-414
47. Cowley D.S., Dager S.R., Roy-Byrne P.P., Avery D.H., and Dunner D.L. Lactate vulnerability after alprazolam versus placebo treatment of panic disorder. Biol. Psychiatry 30 (1991) 49-56
48. Dager S.R., Friedman S.D., Heide A., Layton M.E., Richards T., and Artru A. Two-dimensional proton echo-planar spectroscopic imaging of brain metabolic changes during lactate-induced panic. Arch. Gen. Psychiatry 56 (1999) 70-77
49. 1H-MRS investigation of brain metabolic changes during lactate-induced panic. Psychiatry Res. 76 (1997) 89-99
50. Dager S.R., Strauss W.L., Marro K.I., Richards T.L., Metzger G.D., and Artru A.A. Proton magnetic resonance spectroscopy investigation of hyperventilation in subjects with panic disorder and comparison subjects. Am. J. Psychiatry 152 (1995) 666-672
51. Deakin J.F.W., and Graeff F.G. 5-HT and mechanisms of defence. J. Psychopharmacol. 5 (1991) 305-315
52. de Leeuw A.S., Den Boer J.A., Slaap B.R., and Westenberg H.G. Pentagastrin has panic-inducing properties in obsessive compulsive disorder. Psychopharmacol. (Berl.) 126 (1996) 339-344
53. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch. Gen. Psychiatry 46 (1989) 511-517
54. Dillon D.J., Gorman J.M., Liebowitz M.R., Fyer A.J., and Klein D.F. Measurement of lactate-induced panic and anxiety. Psychiatry Res. 20 (1987) 97-105
55. Ehlers A., Margraf J., Roth W.T., Taylor C.B., Maddock R.J., and Sheikh J. Lactate infusions and panic attacks: do patients and controls respond differently?. Psychiatry Res. 17 (1986) 295-308
56. Erzegovesi S., Martucci L., Henin M., and Bellodi L. Low versus standard dose mCPP challenge in obsessive-compulsive patients. Neuropsychopharmacology 24 (2001) 31-36
57. Eser D., Schule C., Baghai T., Floesser A., Krebs-Brown A., and Enunwa M. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacol. (Berl.) 192 (2007) 479-487
58. Facchinetti F., Romano G., Fava M., and Genazzani A.R. Lactate infusion induces panic attacks in patients with premenstrual syndrome. Psychosom. Med. 54 (1992) 288-296
59. Friedman S.D., Mathis C.M., Hayes C., Renshaw P., and Dager S.R. Brain pH response to hyperventilation in panic disorder: preliminary evidence for altered acid-base regulation. Am. J. Psychiatry 163 (2006) 710-715
60. 2 challenge of patients with panic disorder. Am. J. Psychiatry 144 (1987) 1080-1082
61. Ganong W. Review of Medical Physiology. 18 ed. (1997), Appleton and Lange, Stamford, CT
62. George D.T., Glue P., Bacher J.D., Waxman R.P., and Nutt D.J. Lactate-induced electrolyte changes in the cerebrospinal fluid of rabbits. Biol. Psychiatry 27 (1990) 104-108
63. George D.T., Lindquist T., Nutt D.J., Ragan P.W., Alim T., and McFarlane V. Effect of chloride or glucose on the incidence of lactate-induced panic attacks. Am J. Psychiatry 152 (1995) 692-697
64. George D.T., Nutt D.J., Walker W.V., Porges S.W., Adinoff B., and Linnoila M. Lactate and hyperventilation substantially attenuate vagal tone in normal volunteers. A possible mechanism of panic provocation?. Arch. Gen. Psychiatry 46 (1989) 153-156
65. Germine M., Goddard A.W., Woods S.W., Charney D.S., and Heninger G.R. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol. Psychiatry 32 (1992) 457-461
66. Gibbs D.M. Hyperventilation-induced cerebral ischemia in panic disorder and effect of nimodipine. Am. J. Psychiatry 149 (1992) 1589-1591
67. Goetz R.R., Klein D.F., and Gorman J.M. Consistencies between recalled panic and lactate-induced panic. Anxiety 1 (1994) 31-36
68. 2 challenge?. J. Psychopharmacol. 17 (2003) 265-268
69. Gorman J.M., Askanazi J., Liebowitz M.R., Fyer A.J., Stein J., and Kinney J.M. Response to hyperventilation in a group of patients with panic disorder. Am. J. Psychiatry 141 (1984) 857-861
70. Gorman J.M., Battista D., Goetz R.R., Dillon D.J., Liebowitz M.R., and Fyer A.J. A comparison of sodium bicarbonate and sodium lactate infusion in the induction of panic attacks. Arch. Gen. Psychiatry 46 (1989) 145-150
71. Gorman J.M., Goetz R.R., Dillon D., Liebowitz M.R., Fyer A.J., and Davies S. Sodium D-lactate infusion of panic disorder patients. Neuropsychopharmacology 3 (1990) 181-189
72. Gorman J.M., Goetz R.R., Uy J., Ross D., Martinez J., and Fyer A.J. Hyperventilation occurs during lactate-induced panic. Journal of Anxiety Disorders 2 (1988) 193-202
73. Gorman J.M., Kent J.M., Sullivan G.M., and Coplan J.D. Neuroanatomical hypothesis of panic disorder, revised. Am. J. Psychiatry 157 (2000) 493-505
74. Gorman J.M., Levy G.F., Liebowitz M.R., McGrath P., Appleby I.L., and Dillon D.J. Effect of acute beta-adrenergic blockade on lactate-induced panic. Arch. Gen. Psychiatry 40 (1983) 1079-1082
75. Gorman J.M., Papp L., and Donald F.K. Biological models of panic disorder. In: Noyes R., Roth M., and Burrows G.D. (Eds). Handbook of Anxiety Vol. 3 (1990), Elsevier, New York, NY
76. Gorman J.M., Papp L.A., Coplan J., Martinez J., Liebowitz M.R., and Klein D.F. The effect of acetazolamide on ventilation in panic disorder patients. Am. J. Psychiatry 150 (1993) 1480-1484
77. 2 and hyperventilation in patients with panic disorder. Am. J. Psychiatry 151 (1994) 547-553
78. Graeff F.G. Serotonin, the periaqueductal gray and panic. Neurosci. Biobehav. Rev. 28 (2004) 239-259
79. Graeff F.G., Garcia-Leal C., Del-Ben C.M., and Guimaraes F.S. Does the panic attack activate the hypothalamic-pituitary-adrenal axis?. An. Acad. Bras. Cienc. 77 (2005) 477-491
80. Griez E., de Loof C., Pols H., Zandbergen J., and Lousberg H. Specific sensitivity of patients with panic attacks to carbon dioxide inhalation. Psychiatry Res. 31 (1990) 193-199
81. 2 inhalation: insight into panic mechanisms?. Eur. Arch. Psychiatry Neurol. Sci. 236 (1987) 369-371
82. 2 on panic anxiety. Compr. Psychiatry 29 (1988) 490-497
83. Griez, E.J., Colasanti, A., van Diest, R., Salamon, E. and Schruers, K. (2007) Carbon dioxide inhalation induces dose-dependent and age-related negative affectivity. PLoS ONE, 2: e987.
84. 2 vulnerability in panic disorder. Psychiatry Res. 20 (1987) 87-95
85. Griez E.J.L. Anxiety disorders: an introduction to clinical management and research (2001), Wiley, New York, NY
86. Gutman D.A., Coplan J., Papp L., Martinez J., and Gorman J. Doxapram-induced panic attacks and cortisol elevation. Psychiatry Res. 133 (2005) 253-261
87. Guttmacher L.B., Murphy D.L., and Insel T.R. Pharmacologic models of anxiety. Compr. Psychiatry 24 (1983) 312-326
88. Hollander E., Liebowitz M.R., DeCaria C., and Klein D.F. Fenfluramine, cortisol, and anxiety. Psychiatry Res. 31 (1990) 211-213
89. Hollander E., Liebowitz M.R., Gorman J.M., Cohen B., Fyer A., and Klein D.F. Cortisol and sodium lactate-induced panic. Arch. Gen. Psychiatry 46 (1989) 135-140
90. Holt P.E., and Andrews G. Provocation of panic: three elements of the panic reaction in four anxiety disorders. Behav. Res. Ther. 27 (1989) 253-261
91. Javanmard M., Shlik J., Kennedy S.H., Vaccarino F.J., Houle S., and Bradwejn J. Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol. Psychiatry 45 (1999) 872-882
92. Jensen C.F., Keller T.W., Peskind E.R., McFall M.E., Veith R.C., and Martin D. Behavioral and neuroendocrine responses to sodium lactate infusion in subjects with posttraumatic stress disorder. Am. J. Psychiatry 154 (1997) 266-268
93. 31P-NMR study. Acta Physiol. Scand. 134 (1988) 295-298
94. Kahn R.S., and Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol. Psychiatry 30 (1991) 1139-1166
95. Katzman M.A., Koszycki D., and Bradwejn J. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder. Depress. Anxiety 20 (2004) 51-58
96. Kaye J., Buchanan F., Kendrick A., Johnson P., Lowry C., and Bailey J. Acute carbon dioxide exposure in healthy adults: evaluation of a novel means of investigating the stress response. J. Neuroendocrinol. 16 (2004) 256-264
97. Kellner M., Herzog L., Yassouridis A., Holsboer F., and Wiedemann K. Possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic. Am. J. Psychiatry 152 (1995) 1365-1367
98. Kent J.M., Coplan J.D., Mawlawi O., Martinez J.M., Browne S.T., and Slifstein M. Prediction of panic response to a respiratory stimulant by reduced orbitofrontal cerebral blood flow in panic disorder. Am. J. Psychiatry 162 (2005) 1379-1381
99. Khan S., Liberzon I., and Abelson J.L. Effects of propranolol on symptom and endocrine responses to pentagastrin. Psychoneuroendocrinology 29 (2004) 1163-1171
100. King M.S., and Baertschi A.J. Ventral pontine catecholaminergic pathway mediates the vasopressin response to splanchnic osmostimulation in conscious rats. Brain Res. 580 (1992) 81-91
101. Klein D.F. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch. Gen. Psychiatry 50 (1993) 306-317
102. Klein D.F., and Ross D.C. Response of panic patients and normal controls to lactate infusions. Psychiatry Res. 19 (1986) 163-167
103. Kondoh Y., Kawase M., and Ohmori S. D-lactate concentrations in blood, urine and sweat before and after exercise. Eur. J. Appl. Physiol. Occup. Physiol. 65 (1992) 88-93
104. Koszycki D., Zacharko R.M., Le Melledo J.M., and Bradwejn J. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress. Anxiety 8 (1998) 1-7
105. Kramer M.S., Cutler N.R., Ballenger J.C., Patterson W.M., Mendels J., and Chenault A. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol. Psychiatry 37 (1995) 462-466
106. Laderach H., and Straub W. Effects of voluntary hyperventilation on glucose, free fatty acids and several glucostatic hormones. Swiss Med. Wkly. 131 (2001) 19-22
107. LeDoux J.E. The emotional brain: the mysterious underpinnings of emotional life (1996), Simon & Schuster, New York, NY
108. Lee Y.J., Curtis G.C., Weg J.G., Abelson J.L., Modell J.G., and Campbell K.M. Panic attacks induced by doxapram. Biol. Psychiatry 33 (1993) 295-297
109. Leverve X.M., and Mustafa I. Lactate: a key metabolite in the intercellular metabolic interplay. Crit. Care 6 (2002) 284-285
110. Ley R. The many faces of Pan: psychological and physiological differences among three types of panic attacks. Behav. Res. Ther. 30 (1992) 347-357
111. Liebowitz M.R., Coplan J.D., Martinez J., Fyer A.J., Dillon D.J., and Campeas R.B. Effects of intravenous diazepam pretreatment on lactate-induced panic. Psychiatry Res. 58 (1995) 127-138
112. Liebowitz M.R., Fyer A.J., Gorman J.M., Campeas R., Levin A., and Davies S.R. Alprazolam in the treatment of panic disorders. J. Clin. Psychopharmacol. 6 (1986) 13-20
113. Liebowitz M.R., Fyer A.J., Gorman J.M., Dillon D., Appleby I.L., and Levy G. Lactate provocation of panic attacks. I. Clinical and behavioral findings. Arch. Gen. Psychiatry 41 (1984) 764-770
114. Liebowitz M.R., Gorman J.M., Fyer A., Dillon D., Levitt M., and Klein D.F. Possible mechanisms for lactate's induction of panic. Am. J. Psychiatry 143 (1986) 495-502
115. Liebowitz M.R., Gorman J.M., Fyer A.J., Levitt M., Dillon D., and Levy G. Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch. Gen. Psychiatry 42 (1985) 709-719
116. Lindsay S., Saqi S., and Bass C. The test-retest reliability of the hyperventilation provocation test. J. Psychosom. Res. 35 (1991) 155-162
117. Lines C., Challenor J., and Traub M. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br. J. Clin. Pharm. 39 (1995) 235-242
118. Liotti M., Brannan S., Egan G., Shade R., Madden L., and Abplanalp B. Brain responses associated with consciousness of breathlessness (air hunger). Proc. Natl. Acad. Sci. USA 98 (2001) 2035-2040
119. Lum L.C. Hyperventilation syndromes in medicine and psychiatry: a review. J. R. Soc. Med. 80 (1987) 229-231
120. Maddock R.J. The lactic acid response to alkalosis in panic disorder: an integrative review. J. Neuropsychiatry Clin. Neurosci. 13 (2001) 22-34
121. Maddock R.J., and Carter C.S. Hyperventilation-induced panic attacks in panic disorder with agoraphobia. Biol. Psychiatry 29 (1991) 843-854
122. Maddock R.J., Carter C.S., and Gietzen D.W. Elevated serum lactate associated with panic attacks induced by hyperventilation. Psychiatry Res. 38 (1991) 301-311
123. Maddock R.J., and Mateo-Bermudez J. Elevated serum lactate following hyperventilation during glucose infusion in panic disorder. Biol. Psychiatry 27 (1990) 411-418
124. Maron E., Toru I., Vasar V., and Shlik J. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. J. Psychopharmacol. 18 (2004) 194-199
125. Martel F.L., Hayward C., Lyons D.M., Sanborn K., Varady S., and Schatzberg A.F. Salivary cortisol levels in socially phobic adolescent girls. Depress. Anxiety 10 (1999) 25-27
126. Masdrakis, V.G., Papakostas, Y.G., Vaidakis, N., Papageorgiou, C. and Pehlivanidis, A. (2007) Caffeine challenge in patients with panic disorder: baseline differences between those who panic and those who do not. Depress. Anxiety [Epub ahead of print].
127. 2 in anxiety. Psychiatry Res. 23 (1988) 285-294
128. Mathew R.J., Wilson W.H., Humphreys D., Lowe J.V., and Wiethe K.E. Cerebral vasodilation and vasoconstriction associated with acute anxiety. Biol. Psychiatry 41 (1997) 782-795
129. Mathew R.J., Wilson W.H., and Tant S. Responses to hypercarbia induced by acetazolamide in panic disorder patients. Am. J. Psychiatry 146 (1989) 996-1000
130. McCann U.D., Morgan C.M., Geraci M., Slate S.O., Murphy D.L., and Post R.M. Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology 17 (1997) 360-369
131. McCann U.D., Slate S.O., Geraci M., Roscow-Terrill D., and Uhde T.W. A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls. Neuropsychopharmacology 16 (1997) 229-237
132. McNaughton N., and Corr P.J. A two-dimensional neuropsychology of defense: fear/anxiety and defensive distance. Neurosci. Biobehav. Rev. 28 (2004) 285-305
133. Mortimore C., and Anderson I.M. d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine. Psychopharmacol. (Berl.) 149 (2000) 251-258
134. Mukaddam-Daher S., Lambert C., and Gutkowska J. Clonidine and ST-91 may activate imidazoline binding sites in the heart to release atrial natriuretic peptide. Hypertension 30 (1997) 83-87
135. Mula M., Pini S., and Cassano G.B. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J. Clin. Psychopharmacol. 27 (2007) 263-272
136. Nakashima K., Yamashita T., Kashiwagi S., Nakayama N., Kitahara T., and Ito H. The effect of sodium bicarbonate on CBF and intracellular pH in man: stable Xe-CT and 31P-MRS. Acta Neurol. Scand. Suppl. 166 (1996) 96-98
137. Nardi A.E., Lopes F.L., Valenca A.M., Nascimento I., Mezzasalma M.A., and Zin W.A. Psychopathological description of hyperventilation-induced panic attacks: a comparison with spontaneous panic attacks. Psychopathology 37 (2004) 29-35
138. Nardi A.E., Nascimento I., Valenca A.M., Lopes F.L., Mezzasalma M.A., and Zin W.A. Panic disorder in a breath-holding challenge test: a simple tool for a better diagnosis. Arq. Neuropsiquiatr. 61 (2003) 718-722
139. Nardi A.E., Valenca A.M., Lopes F.L., de-Melo-Neto V.L., Freire R.C., and Veras A.B. Caffeine and 35% carbon dioxide challenge tests in panic disorder. Hum. Psychopharmacol. 22 (2007) 231-240
140. 2 challenge test-induced panic attacks: a comparison with spontaneous panic attacks. Compr. Psychiatry 47 (2006) 209-214
141. Nardi A.E., Valenca A.M., Nascimento I., Mezzasalma M.A., and Zin W.A. Hyperventilation in panic disorder and social phobia. Psychopathology 34 (2001) 123-127
142. Nardi A.E., Valenca A.M., Nascimento I., and Zin W.A. Hyperventilation challenge test in panic disorder and depression with panic attacks. Psychiatry Res. 105 (2001) 57-65
143. Nardi A.E., Valenca A.M., Nascimento I., and Zin W.A. Panic disorder and obsessive compulsive disorder in a hyperventilation challenge test. J. Affect. Disord. 68 (2002) 335-340
144. Netto C.F., and Guimaraes F.S. Anxiogenic effect of cholecystokinin in the dorsal periaqueductal gray. Neuropsychopharmacology 29 (2004) 101-107
145. Nutt D.J., Glue P., Lawson C., and Wilson S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch. Gen. Psychiatry 47 (1990) 917-925
146. Olson B.R., Freilino M., Hoffman G.E., Stricker E.M., Sved A.F., and Verbalis J.G. c-Fos expression in rat brain and brainstem nuclei in response to treatments that alter food intake and gastric motility. Molec. Cell. Neurosci. 4 (1993) 93-106
147. Otte C., Moritz S., Yassouridis A., Koop M., Madrischewski A.M., and Wiedemann K. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. Neuropsychopharmacology 32 (2007) 232-238
148. Pande A.C., Greiner M., Adams J.B., Lydiard R.B., and Pierce M.W. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol. Psychiatry 46 (1999) 860-862
149. 2 measured with steady-state and Read's rebreathing methods. Respir. Physiol. Neurobiol. 137 (2003) 1-10
150. Papp L.A., Klein D.F., Martinez J., Schneier F., Cole R., and Liebowitz M.R. Diagnostic and substance specificity of carbon-dioxide-induced panic. Am. J. Psychiatry 150 (1993) 250-257
151. Papp L.A., Martinez J.M., Klein D.F., Coplan J.D., Norman R.G., and Cole R. Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Am. J. Psychiatry 154 (1997) 1557-1565
152. Parsons L.M., Egan G., Liotti M., Brannan S., Denton D., and Shade R. Neuroimaging evidence implicating cerebellum in the experience of hypercapnia and hunger for air. Proc. Natl. Acad. Sci. USA 98 (2001) 2041-2046
153. Perna G., Battaglia M., Garberi A., Arancio C., Bertani A., and Bellodi L. Carbon dioxide/oxygen challenge test in panic disorder. Psychiatry Res. 52 (1994) 159-171
154. Perna G., Bertani A., Gabriele A., Politi E., and Bellodi L. Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo-controlled study. J. Clin. Psychopharmacol. 17 (1997) 173-178
155. Perna G., Bussi R., Allevi L., and Bellodi L. Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. J. Clin. Psychiatry 60 (1999) 379-384
156. Perna G., Cocchi S., Bertani A., Arancio C., and Bellodi L. Pharmacologic effect of toloxatone on reactivity to the 35% carbon dioxide challenge: a single-blind, random, placebo-controlled study. J. Clin. Psychopharmacol. 14 (1994) 414-418
157. Peskind E.R., Jensen C.F., Pascualy M., Tsuang D., Cowley D., and Martin D.C. Sodium lactate and hypertonic sodium chloride induce equivalent panic incidence, panic symptoms, and hypernatremia in panic disorder. Biol. Psychiatry 44 (1998) 1007-1016
158. Pitts Jr. F.N., and McClure Jr. J.N. Lactate metabolism in anxiety neurosis. N. Engl. J. Med. 277 (1967) 1329-1336
159. Pohl R., Yeragani V.K., and Balon R. Effects of isoproterenol in panic disorder patients after antidepressant treatment. Biol. Psychiatry 28 (1990) 203-214
160. Pohl R., Yeragani V.K., Balon R., Rainey J.M., Lycaki H., and Ortiz A. Isoproterenol-induced panic attacks. Biol. Psychiatry 24 (1988) 891-902
161. Pols H., Verburg K., Hauzer R., Meijer J., and Griez E. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients. Biol. Psychiatry 40 (1996) 913-917
162. 2 challenge. J. Clin. Psychiatry 57 (1996) 539-542
163. Posse S., Dager S.R., Richards T.L., Yuan C., Ogg R., and Artru A.A. In vivo measurement of regional brain metabolic response to hyperventilation using magnetic resonance: proton echo planar spectroscopic imaging (PEPSI). Magn. Reson. Med. 37 (1997) 858-865
164. Potokar J., Lawson C., Wilson S., and Nutt D. Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. Biol. Psychiatry 46 (1999) 1709-1711
165. Potts N.L., Davidson J.R., Krishnan K.R., Doraiswamy P.M., and Ritchie J.C. Levels of urinary free cortisol in social phobia. J. Clin. Psychiatry Suppl. 52 (1991) 41-42
166. 2 challenge and risk for developing panic attacks: a controlled 6- and 12-month follow-up in a nonclinical sample. J. Anxiety Disord. 20 (2006) 1158-1167
167. Raedler T.J., Jahn H., Goedeken B., Gescher D.M., Kellner M., and Wiedemann K. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks. Depress. Anxiety 23 (2006) 139-144
168. Rasmussen S.A., Goodman W.K., Woods S.W., Heninger G.R., and Charney D.S. Effects of yohimbine in obsessive compulsive disorder. Psychopharmacol. (Berl.) 93 (1987) 308-313
169. Rassovsky Y., and Kushner M.G. Carbon dioxide in the study of panic disorder: issues of definition, methodology, and outcome. J. Anxiety Disord. 17 (2003) 1-32
170. Richerson G.B. Serotonergic neurons as carbon dioxide sensors that maintain pH homeostasis. Nat. Rev. Neurosci. 5 (2004) 449-461
171. Sanderson W.C., Rapee R.M., and Barlow D.H. The influence of an illusion of control on panic attacks induced via inhalation of 5.5% carbon dioxide-enriched air. Arch. Gen. Psychiatry 46 (1989) 157-162
172. Schenberg L.C., Bittencourt A.S., Sudre E.C., and Vargas L.C. Modeling panic attacks. Neurosci. Biobehav. Rev. 25 (2001) 647-659
173. Schmidt N.B., Maner J.K., and Zvolensky M.J. Reactivity to challenge with carbon dioxide as a prospective predictor of panic attacks. Psychiatry Res. 151 (2007) 173-176
174. 2 challenge in patients with panic disorder. J. Abnorm. Psychol. 106 (1997) 630-638
175. Schruers K., van Diest R., Overbeek T., and Griez E. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res. 113 (2002) 237-243
176. 2 challenge in patients
177. Severson C.A., Wang W., Pieribone V.A., Dohle C.I., and Richerson G.B. Midbrain serotonergic neurons are central pH chemoreceptors. Nat. Neurosci. 6 (2003) 1139-1140
178. Shekhar A., Johnson P.L., Sajdyk T.J., Fitz S.D., Keim S.R., and Kelley P.E. Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus. J. Neurosci. 26 (2006) 9205-9215
179. Shekhar A., and Keim S.R. The circumventricular organs form a potential neural pathway for lactate sensitivity: implications for panic disorder. J. Neurosci. 17 (1997) 9726-9735
180. Shlik J., Aluoja A., Vasar V., Vasar E., Podar T., and Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J. Psychiatry Neurosci. 22 (1997) 332-340
181. Siesjo B.K. Lactic acidosis in the brain: occurrence, triggering mechanisms and pathophysiological importance. Ciba. Found. Symp. 87 (1982) 77-100
182. Southwick S.M., Krystal J.H., Bremner J.D., Morgan III C.A., Nicolaou A.L., and Nagy L.M. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry 54 (1997) 749-758
183. Spinhoven P., Onstein E.J., Sterk P.J., and Le Haen-Versteijnen D. The hyperventilation provocation test in panic disorder. Behav. Res. Ther. 30 (1992) 453-461
184. Strohle A., Feller C., Onken M., Godemann F., Heinz A., and Dimeo F. The acute antipanic activity of aerobic exercise. Am. J. Psychiatry 162 (2005) 2376-2378
185. Strohle A., Holsboer F., and Rupprecht R. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology 22 (2000) 251-256
186. Strohle A., Kellner M., Holsboer F., and Wiedemann K. Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. Biol. Psychiatry 45 (1999) 321-326
187. Strohle A., Kellner M., Holsboer F., and Wiedemann K. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. Am. J. Psychiatry 158 (2001) 1514-1516
188. Strohle A., Kellner M., Yassouridis A., Holsboer F., and Wiedemann K. Effect of flumazenil in lactate-sensitive patients with panic disorder. Am. J. Psychiatry 155 (1998) 610-612
189. Strohle A., Romeo E., di Michele F., Pasini A., Hermann B., and Gajewsky G. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch. Gen. Psychiatry 60 (2003) 161-168
190. Swain J., Koszycki D., Shlik J., and Bradwejn J. Pharmacological challenge agents in anxiety. In: Nutt D.J., and Ballenger J.C. (Eds). Anxiety disorders (2003), Blackwell Science, Malden, MA pp. xi, 542
191. Targum S.D., and Marshall L.E. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res. 28 (1989) 295-306
192. Toru I., Shlik J., Maron E., Vasar V., and Nutt D.J. Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. Psychopharmacol. (Berl.) 186 (2006) 107-112
193. Tsacopoulos M., and Magistretti P.J. Metabolic coupling between glia and neurons. J. Neurosci. 16 (1996) 877-885
194. Uhde T.W., Tancer M.E., Gelernter C.S., and Vittone B.J. Normal urinary free cortisol and postdexamethasone cortisol in social phobia: comparison to normal volunteers. J. Affect. Disord. 30 (1994) 155-161
195. Uhlenhuth E.H., Leon A.C., and Matuzas W. Psychopathology of panic attacks in panic disorder. J. Affect. Disord. 92 (2006) 55-62
196. Uhlenhuth E.H., Matuzas W., Warner T.D., Paine S., Lydiard R.B., and Pollack M.H. Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication. J. Clin. Psychopharmacol. 20 (2000) 622-627
197. Valenca A.M., Nardi A.E., Mezzasalma M.A., Nascimento I., Lopes F.L., and Zin W.A. Clonidine in respiratory panic disorder subtype. Arq. Neuropsiquiatr. 62 (2004) 396-398
198. Van den Hout M.A., and Griez E. Panic symptoms after inhalation of carbon dioxide. Br. J. Psychiatry 144 (1984) 503-507
199. 2 exposure. Am. J. Psychiatry 144 (1987) 788-791
200. Vanderhaeghen J.J., Signeau J.C., and Gepts W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257 (1975) 604-605
201. 2 challenge results in hypothalamic-pituitary-adrenal activation in healthy volunteers. J. Psychopharmacol. 19 (2005) 243-247
202. 2 challenge induced HPA axis activation in panic. Int. J. Neuropsychopharmacol. 1 (2006) 1-8
203. van Megen H.J., Westenberg H.G., den Boer J.A., Haigh J.R., and Traub M. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacol. (Berl.) 114 (1994) 449-455
204. van Megen H.J., Westenberg H.G., den Boer J.A., Slaap B., and Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacol. (Berl.) 129 (1997) 357-364
205. 31P NMR measurement of cerebral lactate, high-energy phosphate levels, and pH in humans during voluntary hyperventilation: associated EEG, capnographic, and Doppler findings. Magn. Reson. Med. 10 (1989) 182-193
206. van Vliet I.M., Westenberg H.G., Slaap B.R., den Boer J.A., and Ho Pian K.L. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls. Biol. Psychiatry 42 (1997) 76-78
207. Veltman D.J., van Zijderveld G.A., and van Dyck R. Epinephrine infusions in panic disorder: a double-blind placebo-controlled study. J. Affect. Disord. 39 (1996) 133-140
208. Verburg K., Griez E., Meijer J., and Pols H. Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge. Am. J. Psychiatry 152 (1995) 1081-1083
209. 2 challenge. In: Griez E.J.L. (Ed). Anxiety disorders: an introduction to clinical management and research (2001), Wiley, Chichester, NY pp. xxii, 380
210. Verburg K., Pols H., de Leeuw M., and Griez E. Reliability of the 35% carbon dioxide panic provocation challenge. Psychiatry Res. 78 (1998) 207-214
211. Vickers K., and McNally R.J. Respiratory symptoms and panic in the National Comorbidity Survey: a test of Klein's suffocation false alarm theory. Behav. Res. Ther. 43 (2005) 1011-1018
212. 31P NMR study. J. Cereb. Blood Flow Metab. 9 (1989) 417-421
213. + conductance. J. Neurosci. 22 (2002) 1256-1265
214. Wemmie J.A., Askwith C.C., Lamani E., Cassell M.D., Freeman Jr. J.H., and Welsh M.J. Acid-sensing ion channel 1 is localized in brain regions with high synaptic density and contributes to fear conditioning. J. Neurosci. 23 (2003) 5496-5502
215. Wemmie J.A., Coryell M.W., Askwith C.C., Lamani E., Leonard A.S., and Sigmund C.D. Overexpression of acid-sensing ion channel 1a in transgenic mice increases acquired fear-related behavior. Proc. Natl. Acad. Sci. USA 101 (2004) 3621-3626
216. Wiedemann K., Jahn H., Yassouridis A., and Kellner M. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch. Gen. Psychiatry 58 (2001) 371-377
217. Wilhelm F.H., Gerlach A.L., and Roth W.T. Slow recovery from voluntary hyperventilation in panic disorder. Psychosom. Med. 63 (2001) 638-649
218. Yeragani V.K., Balon R., Rainey J.M., Ortiz A., Berchou R., and Lycaki H. Effects of laboratory-induced panic-anxiety on subsequent provocative infusions. Psychiatry Res. 23 (1988) 161-166
219. Yeragani V.K., Pohl R., Balon R., Rainey J.M., Berchou R., and Ortiz A. Sodium lactate infusions after treatment with tricyclic antidepressants: behavioral and physiological findings. Biol. Psychiatry 24 (1988) 767-774
220. Zandbergen J., Lousberg H.H., Pols H., de Loof C., and Griez E.J. Hypercarbia versus hypocarbia in panic disorder. J. Affect. Disord. 18 (1990) 75-81
221. 2 in panic disorder. Psychiatry Res. 39 (1991) 13-19
222. Zhou F.Q. Pyruvate in the correction of intracellular acidosis: a metabolic basis as a novel superior buffer. Am. J. Nephrol. 25 (2005) 55-63
223. Zwanzger P., Baghai T.C., Schuele C., Strohle A., Padberg F., and Kathmann N. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 25 (2001) 699-703
224. Zwanzger P., Eser D., Aicher S., Schule C., Baghai T.C., and Padberg F. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology 28 (2003) 979-984
225. Zwanzger P., Eser D., Padberg F., Baghai T.C., Schule C., and Rotzer F. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress. Anxiety 18 (2003) 140-143